Oportuzumab monatox

N/A

Report date: 2024/11/25 20:00:28

Base Information

Drug NameOportuzumab monatox
Drug Alias Name莫奥珠单抗蒙托-奥珀妥珠单抗ProxiniumViciniumVicineum +[10] 
ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionElongation factor 2 inhibitorsProtein biosynthesis inhibitorsAnti-EpCAM
TargetsElongation factor 2Epithelial cell adhesion molecule
Therapy Area/IndicationsUrinary Bladder NeoplasmsMouth NeoplasmsHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesViventia Biotech IncSesen Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesSesen Bio IncEczacibasi Pharmaceuticals MarketingNational Cancer Institute +[4] 
Inactive CompaniesBaxter Oncology GmbhQilu Pharmaceutical Co Ltd
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsMouth NeoplasmsHead and Neck NeoplasmsNeoplasms, Squamous Cell +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank